Tumor Antigen Vaccines

Somatic mutations within tumor cells give rise to tumor-specific MHC I restricted epitopes that can be recognized by the immune system to differentiate cancer from normal cells. Thus, generally occurring shared tumor antigens (e.g. KRAS) are candidates for cancer vaccines. A tumor antigen vaccine made of tumor antigens (peptides) stimulates the host's immune system to neutralize cancer cells. Our Clinical Peptides and Pools meet the need for high quality yet fast and affordable peptides for development of vaccines.

Why Work with JPT?

  • Two decades worth of experience in peptide drug development and peptide chemistry
  • Our algorithms (based on 2.5 million synthesized peptides) rank peptides for manufacturability, stability, solubility, hydrophobicity and more
  • Regulated according to ISO 9001:2015 standards 

Clinical Peptides & Pools

JPT’s Clinical Peptides & Pools for for development of immunotherapy & cell therapy are produced in production environments regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy such as peptide vaccines. Depending on the specifics of your immunotherapy protocols, the resulting products are applicable in clinical applications.

PepMix™ Peptide Pools

Our antigen spanning PepMixes™ are available in a large variety of off-the-shelf peptide pools (e.g. for EBV, HCMV, Adenovirus, BKV, HHV6 and tumor associated antigens) or customized for your clinical application and antigens (e.g. epitope & neo-epitope, overlapping peptide pools and more). We also offer a wide variety of standardization and control pools such as CEFX Pools and HCMV (pp65).
use of peptide vaccination

Check our list of products, click and go.

Get a quote